Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Beth Karlan

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Genes & Molecular Sequences

Concepts & Ideas

Physiology

Chemicals & Drugs

Procedures

Mass Screening

Anatomy

Cultured Tumor Cells

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Ioffe Y J; Li A J; Walsh C S; Karlan B Y; Leuchter R; Forscher C; Cass I
Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.
Xing Deyin; Scangas George; Nitta Mai; He Lei; Xu Xuan; Ioffe Yevgeniya J M; Aspuria Paul-Joseph; Hedvat Cyrus Y; Anderson Matthew L; Oliva Esther; Karlan Beth Y; Mohapatra Gayatry; Orsulic Sandra
A role for BRCA1 in uterine leiomyosarcoma.
Karam Amer K; Chiang Jing Wang; Fung Ewina; Nossov Vladimir; Karlan Beth Y
Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Beth Karlan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Ioffe Y J; Li A J; Walsh C S; Karlan B Y; Leuchter R; Forscher C; Cass I
Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.
Gynecologic oncology 2009;115(3):466-71.
2009: Xing Deyin; Scangas George; Nitta Mai; He Lei; Xu Xuan; Ioffe Yevgeniya J M; Aspuria Paul-Joseph; Hedvat Cyrus Y; Anderson Matthew L; Oliva Esther; Karlan Beth Y; Mohapatra Gayatry; Orsulic Sandra
A role for BRCA1 in uterine leiomyosarcoma.
Cancer research 2009;69(21):8231-5.
2009: Karam Amer K; Chiang Jing Wang; Fung Ewina; Nossov Vladimir; Karlan Beth Y
Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Gynecologic oncology 2009;114(2):246-52.
2009: Winer Eric; Gralow Julie; Diller Lisa; Karlan Beth; Loehrer Patrick; Pierce Lori; Demetri George; Ganz Patricia; Kramer Barnett; Kris Mark; Markman Maurie; Mayer Robert; Pfister David; Raghavan Derek; Ramsey Scott; Reaman Gregory; Sandler Howard; Sawaya Raymond; Schuchter Lynn; Sweetenham John; Vahdat Linda; Schilsky Richard L;
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(5):812-26.
2008: Walsh Christine S; Ogawa Seishi; Scoles Daniel R; Miller Carl W; Kawamata Norihiko; Narod Steven A; Koeffler H Phillip; Karlan Beth Y
Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7645-51.
2008: Walsh Christine S; Karlan Beth Y
Lymphadenectomy's role in early endometrial cancer: prognostic or therapeutic?
Journal of the National Cancer Institute 2008;100(23):1660-1.
2008: Wolf I; Levanon-Cohen S; Bose S; Ligumsky H; Sredni B; Kanety H; Kuro-o M; Karlan B; Kaufman B; Koeffler H P; Rubinek T
Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer.
Oncogene 2008;27(56):7094-105.
2008: Fejzo Marlena S; Dering Judy; Ginther Chuck; Anderson Lee; Ramos Lilian; Walsh Christine; Karlan Beth; Slamon Dennis J
Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Genes, chromosomes & cancer 2008;47(10):873-83.
2008: Wakimoto Naoki; Yin Dong; O'Kelly James; Haritunians Talin; Karlan Beth; Said Jonathan; Xing Hongtao; Koeffler H Phillip
Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo.
Cancer science 2008;99(9):1793-7.
2008: Narod S A; Neuhausen S; Vichodez G; Armel S; Lynch H T; Ghadirian P; Cummings S; Olopade O; Stoppa-Lyonnet D; Couch F; Wagner T; Warner E; Foulkes W D; Saal H; Weitzel J; Tulman A; Poll A; Nam R; Sun P; Danquah Jessica; Domchek Susan; Tung Nadine; Ainsworth Peter; Horsman Douglas; Kim-Sing Charmaine; Maugard Christine; Eisen Andrea; Daly Mary; McKinnon Wendy; Wood Marie; Isaacs Claudine; Gilchrist Dawna; Karlan Beth; Nedelcu Raluca; Meschino Wendy; Garber Judy; Pasini Barbara; Manoukian Siranoush; Bellati Christina
Rapid progression of prostate cancer in men with a BRCA2 mutation.
British journal of cancer 2008;99(2):371-4.
2008: O'Kelly James; Chung Alice; Lemp Nathan; Chumakova Katya; Yin Dong; Wang He-Jing; Said Jonathan; Gui Dorina; Miller Carl W; Karlan Beth Y; Koeffler H Phillip
Functional domains of CCN1 (Cyr61) regulate breast cancer progression.
International journal of oncology 2008;33(1):59-67.
2008: Walsh Christine S; Ogawa Seishi; Karahashi Hisae; Scoles Daniel R; Pavelka James C; Tran Hang; Miller Carl W; Kawamata Norihiko; Ginther Charles; Dering Judy; Sanada Masashi; Nannya Yasuhito; Slamon Dennis J; Koeffler H Phillip; Karlan Beth Y
ERCC5 is a novel biomarker of ovarian cancer prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(18):2952-8.
2008: Li Andrew J; Scoles Daniel R; Armstrong Klara U M; Karlan Beth Y
Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas.
Gynecologic oncology 2008;109(2):220-5.
2008: Swisher Elizabeth M; Sakai Wataru; Karlan Beth Y; Wurz Kaitlyn; Urban Nicole; Taniguchi Toshiyasu
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
Cancer research 2008;68(8):2581-6.
2008: Karlan Beth Y
Improving efficiencies in translational science.
Gynecologic oncology 2008;108(3):461.
2008: Sakai Wataru; Swisher Elizabeth M; Karlan Beth Y; Agarwal Mukesh K; Higgins Jake; Friedman Cynthia; Villegas Emily; Jacquemont Céline; Farrugia Daniel J; Couch Fergus J; Urban Nicole; Taniguchi Toshiyasu
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Nature 2008;451(7182):1116-20.
2007: Pavelka James C; Li Andrew J; Karlan Beth Y
Hereditary ovarian cancer--assessing risk and prevention strategies.
Obstetrics and gynecology clinics of North America 2007;34(4):651-65, vii-viii.
2007: Li Andrew J; Elmore R Geoffrey; Pavelka James C; Karlan Beth Y
Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology.
Gynecologic oncology 2007;107(3):420-3.
2007: Walsh Christine S; Karlan B Y
Contemporary progress in ovarian cancer screening.
Current oncology reports 2007;9(6):485-93.
2007: Lancaster Johnathan M; Powell C Bethan; Kauff Noah D; Cass Ilana; Chen Lee-May; Lu Karen H; Mutch David G; Berchuck Andrew; Karlan Beth Y; Herzog Thomas J;
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
Gynecologic oncology 2007;107(2):159-62.
2007: Karlan Beth Y
Can lifestyle influence genetics?
Nature clinical practice. Oncology 2007;4(10):555.
2007: Wolf Ido; Bose Shikha; Desmond Julian C; Lin Bryan T; Williamson Elizabeth A; Karlan Beth Y; Koeffler H Phillip
Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer.
Breast cancer research and treatment 2007;105(2):139-55.
2007: Kotsopoulos Joanne; Lubinski Jan; Lynch Henry T; Klijn Jan; Ghadirian Parviz; Neuhausen Susan L; Kim-Sing Charmaine; Foulkes William D; Moller Pal; Isaacs Claudine; Domchek Susan; Randall Susan; Offit Kenneth; Tung Nadine; Ainsworth Peter; Gershoni-Baruch Ruth; Eisen Andrea; Daly Mary; Karlan Beth; Saal Howard M; Couch Fergus; Pasini Barbara; Wagner Teresa; Friedman Eitan; Rennert Gad; Eng Charis; Weitzel Jeffrey; Sun Ping; Narod Steven A; Garber J; Osborne M; Fishman D; McLennan J; McKinnon W; Merajver S; Olsson H; Provencher D; Pasche B; Evans G; Meschino W S; Lemire E; Chudley A; Rayson D; Bellati C
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast cancer research and treatment 2007;105(2):221-8.
2007: Karlan Beth Y; Berchuck Andrew; Mutch David
The role of genetic testing for cancer susceptibility in gynecologic practice.
Obstetrics and gynecology 2007;110(1):155-67.
2007: Wolf Ido; O'Kelly James; Wakimoto Naoki; Nguyen Anh; Amblard Franck; Karlan Beth Y; Arbiser Jack L; Koeffler H Phillip
Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest.
International journal of oncology 2007;30(6):1529-37.
2007: Kotsopoulos Joanne; Ghadirian Parviz; El-Sohemy Ahmed; Lynch Henry T; Snyder Carrie; Daly Mary; Domchek Susan; Randall Susan; Karlan Beth; Zhang Phil; Zhang Shiyu; Sun Ping; Narod Steven A
The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(5):912-6.
2007: Karlan Beth Y; McIntosh Martin
The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(11):1303-4.
2007: Wolf Ido; Bose Shikha; Williamson Elizabeth A; Miller Carl W; Karlan Beth Y; Koeffler H Phillip
FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.
International journal of cancer. Journal international du cancer 2007;120(5):1013-22.
2007: Santillan Antonio; Karam Amer K; Li Andrew J; Giuntoli Robert; Gardner Ginger J; Cass Ilana; Karlan Beth Y; Bristow Robert E
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Gynecologic oncology 2007;104(3):686-90.
2007: Walsh Christine S; Miller Carl W; Karlan Beth Y; Koeffler H Phillip
Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Gynecologic oncology 2007;104(3):660-4.
2007: Axtell Allison E; Lee Margaret H; Bristow Robert E; Dowdy Sean C; Cliby William A; Raman Steven; Weaver John P; Gabbay Mojan; Ngo Michael; Lentz Scott; Cass Ilana; Li Andrew J; Karlan Beth Y; Holschneider Christine H
Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(4):384-9.
2007: Karam Amer K; Santillan Antonio; Bristow Robert E; Giuntoli Robert; Gardner Ginger J; Cass Ilana; Karlan Beth Y; Li Andrew J
Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome.
Gynecologic oncology 2007;104(2):377-80.
2007: McLaughlin John R; Risch Harvey A; Lubinski Jan; Moller Pal; Ghadirian Parviz; Lynch Henry; Karlan Beth; Fishman David; Rosen Barry; Neuhausen Susan L; Offit Kenneth; Kauff Noah; Domchek Susan; Tung Nadine; Friedman Eitan; Foulkes William; Sun Ping; Narod Steven A;
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
The lancet oncology 2007;8(1):26-34.
2007: Scoles Daniel R; Pavelka James; Cass Ilana; Tran Hang; Baldwin Rae L; Armstrong Klara; Karlan Beth Y
Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT.
Gynecologic oncology 2007;104(1):120-8.
2007: Lerner Dimitry L; Walsh Christine S; Cass Ilana; Karlan Beth Y; Li Andrew J
The prognostic significance of thrombocytosis in uterine papillary serous carcinomas.
Gynecologic oncology 2007;104(1):91-4.
2006: Guillem José G; Wood William C; Moley Jeffrey F; Berchuck Andrew; Karlan Beth Y; Mutch David G; Gagel Robert F; Weitzel Jeffrey; Morrow Monica; Weber Barbara L; Giardiello Francis; Rodriguez-Bigas Miguel A; Church James; Gruber Stephen; Offit Kenneth;
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4642-60.
2006: Guillem José G; Wood William C; Moley Jeffrey F; Berchuck Andrew; Karlan Beth Y; Mutch David G; Gagel Robert F; Weitzel Jeffrey; Morrow Monica; Weber Barbara L; Giardiello Francis; Rodriguez-Bigas Miguel A; Church James; Gruber Stephen; Offit Kenneth
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
Annals of surgical oncology 2006;13(10):1296-321.
2006: Pavelka James C; Brown Rebecca S; Karlan Beth Y; Cass Ilana; Leuchter Ronald S; Lagasse Leo D; Li Andrew J
Effect of obesity on survival in epithelial ovarian cancer.
Cancer 2006;107(7):1520-4.
2006: Gordon Michael S; Matei Daniela; Aghajanian Carol; Matulonis Ursula A; Brewer Molly; Fleming Gini F; Hainsworth John D; Garcia Agustin A; Pegram Mark D; Schilder Russell J; Cohn David E; Roman Lynda; Derynck Mika K; Ng Kimmie; Lyons Benjamin; Allison David E; Eberhard David A; Pham Thinh Q; Dere Randall C; Karlan Beth Y
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(26):4324-32.
2006: Wolf Ido; O'Kelly James; Rubinek Tamar; Tong Min; Nguyen Anh; Lin Bryan T; Tai Hsin-Hsiung; Karlan Beth Y; Koeffler H Phillip
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
Cancer research 2006;66(15):7818-23.
2006: Finch Amy; Beiner Mario; Lubinski Jan; Lynch Henry T; Moller Pal; Rosen Barry; Murphy Joan; Ghadirian Parviz; Friedman Eitan; Foulkes William D; Kim-Sing Charmaine; Wagner Teresa; Tung Nadine; Couch Fergus; Stoppa-Lyonnet Dominique; Ainsworth Peter; Daly Mary; Pasini Babara; Gershoni-Baruch Ruth; Eng Charis; Olopade Olufunmilayo I; McLennan Jane; Karlan Beth; Weitzel Jeffrey; Sun Ping; Narod Steven A;
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
JAMA : the journal of the American Medical Association 2006;296(2):185-92.
2006: Karlan Beth Y
Evolution through intelligent design.
Gynecologic oncology 2006;102(1):1-4.
2006: Chiang Jing Wang; Karlan Beth Y; Cass Llana; Baldwin Rae Lynn
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
Gynecologic oncology 2006;101(3):403-10.
2006: Wei Susan H; Balch Curtis; Paik Henry H; Kim Yoo-Sung; Baldwin Rae Lynn; Liyanarachchi Sandya; Li Lang; Wang Zailong; Wan Joseph C; Davuluri Ramana V; Karlan Beth Y; Gifford Gillian; Brown Robert; Kim Sun; Huang Tim H-M; Nephew Kenneth P
Prognostic DNA methylation biomarkers in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(9):2788-94.
2006: Kotsopoulos Joanne; Lubinski Jan; Neuhausen Susan L; Lynch Henry T; Rosen Barry; Ainsworth Peter; Moller Pal; Ghadirian Parviz; Isaacs Claudine; Karlan Beth; Sun Ping; Narod Steven A
Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Gynecologic oncology 2006;100(1):83-8.
2006: Friedman Eitan; Kotsopoulos Joanne; Lubinski Jan; Lynch Henry T; Ghadirian Parviz; Neuhausen Susan L; Isaacs Claudine; Weber Barbara; Foulkes William D; Moller Pal; Rosen Barry; Kim-Sing Charmaine; Gershoni-Baruch Ruth; Ainsworth Peter; Daly Mary; Tung Nadine; Eisen Andrea; Olopade Olufunmilayo I; Karlan Beth; Saal Howard M; Garber Judy E; Rennert Gad; Gilchrist Dawna; Eng Charis; Offit Kenneth; Osborne Michael; Sun Ping; Narod Steven A;
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.
Breast cancer research : BCR 2006;8(2):R15.
2005: Li Andrew J; Lerner Dimitry L; Gapuzan Maria-Emily R; Karlan Beth Y
AIB1 polymorphisms predict aggressive ovarian cancer phenotype.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(12):2919-22.
2005: Cass Ilana; Holschneider Christine; Datta Nandini; Barbuto Denise; Walts Ann E; Karlan Beth Y
BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
Obstetrics and gynecology 2005;106(6):1327-34.
2005: Li Andrew J; Giuntoli Robert L; Drake Richard; Byun Sharon Young; Rojas Francisco; Barbuto Denise; Klipfel Nancy; Edmonds Pamela; Miller David S; Karlan Beth Y
Ovarian preservation in stage I low-grade endometrial stromal sarcomas.
Obstetrics and gynecology 2005;106(6):1304-8.
2005: Byrne Jennifer A; Balleine Rosemary L; Schoenberg Fejzo Marlena; Mercieca Janelle; Chiew Yoke-Eng; Livnat Yael; St Heaps Luke; Peters Gregory B; Byth Karen; Karlan Beth Y; Slamon Dennis J; Harnett Paul; Defazio Anna
Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
International journal of cancer. Journal international du cancer 2005;117(6):1049-54.
2005: Karlan Beth Y
Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources: Committee on Government Reform United States House of Representatives.
Gynecologic oncology 2005;99(2):257-60.
2005: Li Andrew John; Karlan Beth Young
Androgen mediation of thrombocytosis in epithelial ovarian cancer biology.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(22):8015-8.
2005: Walsh Christine; Holschneider Christine; Hoang Yen; Tieu Khai; Karlan Beth; Cass Ilana
Coexisting ovarian malignancy in young women with endometrial cancer.
Obstetrics and gynecology 2005;106(4):693-9.
2005: Holschneider Christine H; Baldwin Rae Lynn; Tumber Kiran; Aoyama Chisa; Karlan Beth Y
The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5756-63.
2005: Kotsopoulos Joanne; Lubinski Jan; Lynch Henry T; Neuhausen Susan L; Ghadirian Parviz; Isaacs Claudine; Weber Barbara; Kim-Sing Charmaine; Foulkes William D; Gershoni-Baruch Ruth; Ainsworth Peter; Friedman Eitan; Daly Mary; Garber Judy E; Karlan Beth; Olopade Olufunmilayo I; Tung Nadine; Saal Howard M; Eisen Andrea; Osborne Michael; Olsson Hakan; Gilchrist Dawna; Sun Ping; Narod Steven A
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Cancer causes & control : CCC 2005;16(6):667-74.
2005: Elkas John C; Berek Jonathan S; Leuchter Ronald; Lagasse Leo D; Karlan Beth Y
Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies.
Gynecologic oncology 2005;97(2):685-92.
2005: Agus David B; Gordon Michael S; Taylor Charles; Natale Ronald B; Karlan Beth; Mendelson David S; Press Michael F; Allison David E; Sliwkowski Mark X; Lieberman Gracie; Kelsey Stephen M; Fyfe Gwen
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2534-43.
2004: Karlan Beth
Profiling the perpetrator.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4663-4.
2004: Karlan Beth Y
The colon is a pelvic organ too: taking the Couric challenge.
Obstetrics and gynecology 2004;104(5 Pt 1):907-9.
2004: McIntosh M W; Drescher C; Karlan B; Scholler N; Urban N; Hellstrom K E; Hellstrom I
Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.
Gynecologic oncology 2004;95(1):9-15.
2004: Liede Alexander; Karlan Beth Y; Narod Steven A
Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):735-42.
2004: Karlan Beth Y
Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis.
Gynecologic oncology 2004;92(2):519-20.
2004: Li Andrew J; Madden Alison C; Cass Ilana; Leuchter Ronald S; Lagasse Leo D; Karlan Beth Y
The prognostic significance of thrombocytosis in epithelial ovarian carcinoma.
Gynecologic oncology 2004;92(1):211-4.
2003: Chen L-M; Yamada S D; Fu Y-S; Baldwin R L; Karlan B Y
Molecular similarities between primary peritoneal and primary ovarian carcinomas.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(6):749-55.
2003: Li Andrew J; Baldwin Rae Lynn; Karlan Beth Y
Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3667-73.
2003: Urban Nicole; McIntosh Martin W; Andersen Marin; Karlan Beth Y
Ovarian cancer screening.
Hematology/oncology clinics of North America 2003;17(4):989-1005, ix.
2003: Li Andrew J; Karlan Beth Y
Surgical advances in the treatment of ovarian cancer.
Hematology/oncology clinics of North America 2003;17(4):945-56.
2003: Li Andrew J; Baldwin Rae Lynn; Karlan Beth Y
Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures.
American journal of obstetrics and gynecology 2003;189(1):22-7.
2003: Modugno Francesmary; Moslehi Roxana; Ness Roberta B; Nelson Deborah Brooks; Belle Steven; Kant Jeffrey A; Wheeler James E; Wonderlick Aimee; Fishman David; Karlan Beth; Risch Harvey; Cramer Daniel W; Dube Marie-Pierre; Narod Steven A
Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States).
Cancer causes & control : CCC 2003;14(5):439-46.
2003: Cass Ilana; Baldwin Rae Lynn; Varkey Taz; Moslehi Roxana; Narod Steven A; Karlan Beth Y
Improved survival in women with BRCA-associated ovarian carcinoma.
Cancer 2003;97(9):2187-95.
2003: Baldwin Rae Lynn; Tran Hang; Karlan Beth Y
Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.
Cancer research 2003;63(6):1413-9.
2003: Arboleda M Jane; Lyons John F; Kabbinavar Fairooz F; Bray Mark R; Snow Bryan E; Ayala Raul; Danino Mordechai; Karlan Beth Y; Slamon Dennis J
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.
Cancer research 2003;63(1):196-206.
2002: Elkas John C; Baldwin Rae Lynn; Pegram Mark; Tseng Yiou; Slamon Dennis; Karlan Beth Y
A human ovarian carcinoma murine xenograft model useful for preclinical trials.
Gynecologic oncology 2002;87(2):200-6.
2002: Memarzadeh S; Holschneider C H; Bristow R E; Jones N L; Fu Y S; Karlan B Y; Berek J S; Farias-Eisner R
FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2002;12(5):454-8.
2002: Gillan Lindsay; Matei Daniela; Fishman David A; Gerbin C S; Karlan Beth Y; Chang David D
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility.
Cancer research 2002;62(18):5358-64.
2002: Matei Daniela; Graeber Thomas G; Baldwin Rae Lynn; Karlan Beth Y; Rao Jianyu; Chang David D
Gene expression in epithelial ovarian carcinoma.
Oncogene 2002;21(41):6289-98.
2002: Buller Richard E; Shahin Mark S; Horowitz Jo Ann; Runnebaum Ingo B; Mahavni Vikas; Petrauskas Stan; Kreienberg Rolf; Karlan Beth; Slamon Dennis; Pegram Mark
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.
Cancer gene therapy 2002;9(7):567-72.
2002: Buller Richard E; Runnebaum Ingo B; Karlan Beth Y; Horowitz Jo Ann; Shahin Mark; Buekers Thomas; Petrauskas Stan; Kreienberg Rolf; Slamon Dennis; Pegram Mark
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Cancer gene therapy 2002;9(7):553-66.
2002: Liede Alexander; Karlan Beth Y; Baldwin Rae Lynn; Platt Lawrence D; Kuperstein Graciela; Narod Steven A
Cancer incidence in a population of Jewish women at risk of ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1570-7.
2002: Wang Jing; Li Andrew J; Karlan Beth Y
Chemotherapy in epithelial ovarian cancer.
Current women's health reports 2002;2(1):20-6.
2002: McIntosh Martin W; Urban Nicole; Karlan Beth
Generating longitudinal screening algorithms using novel biomarkers for disease.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2002;11(2):159-66.
2001: Runnebaum I B; Wang-Gohrke S; Vesprini D; Kreienberg R; Lynch H; Moslehi R; Ghadirian P; Weber B; Godwin A K; Risch H; Garber J; Lerman C; Olopade O I; Foulkes W D; Karlan B; Warner E; Rosen B; Rebbeck T; Tonin P; Dubé M P; Kieback D G; Narod S A
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
Pharmacogenetics 2001;11(7):635-8.
2001: Cass I; Baldwin R L; Fasylova E; Fields A L; Klinger H P; Runowicz C D; Karlan B Y
Allelotype of papillary serous peritoneal carcinomas.
Gynecologic oncology 2001;82(1):69-76.
2001: Narod S A; Sun P; Ghadirian P; Lynch H; Isaacs C; Garber J; Weber B; Karlan B; Fishman D; Rosen B; Tung N; Neuhausen S L
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
Lancet 2001;357(9267):1467-70.
2001: Cass I; Li A J; Runowicz C D; Fields A L; Goldberg G L; Leuchter R S; Lagasse L D; Karlan B Y
Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas.
Gynecologic oncology 2001;80(1):56-61.
2001: Li A J; Karlan B Y
Genetic factors in ovarian carcinoma.
Current oncology reports 2001;3(1):27-32.
2000: Ismail R S; Baldwin R L; Fang J; Browning D; Karlan B Y; Gasson J C; Chang D D
Differential gene expression between normal and tumor-derived ovarian epithelial cells.
Cancer research 2000;60(23):6744-9.
2000: Brown J V; Peters W A; Rettenmaier M A; Karlan B Y; Dillman R A; Smith M R; Drescher C W; Micha J P
A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
Gynecologic oncology 2000;79(3):495-8.
2000: Crump C; McIntosh M W; Urban N; Anderson G; Karlan B Y
Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2000;9(10):1107-11.
2000: Baldwin R L; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan B Y
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Cancer research 2000;60(19):5329-33.
2000: Chen L M; Karlan B Y
Recurrent ovarian carcinoma: is there a place for surgery?
Seminars in surgical oncology 2000;19(1):62-8.
2000: Chen L M; Leuchter R S; Lagasse L D; Karlan B Y
Splenectomy and surgical cytoreduction for ovarian cancer.
Gynecologic oncology 2000;77(3):362-8.
2000: Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet J S; Narod S A
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
American journal of human genetics 2000;66(4):1259-72.
1999: Schummer M; Ng W V; Bumgarner R E; Nelson P S; Schummer B; Bednarski D W; Hassell L; Baldwin R L; Karlan B Y; Hood L
Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas.
Gene 1999;238(2):375-85.
1999: Yamada S D; Baldwin R L; Karlan B Y
Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors.
Gynecologic oncology 1999;75(1):72-7.
1999: Cass I; Baldwin R L; Karlan B Y
Molecular advances in gynecologic oncology.
Current opinion in oncology 1999;11(5):394-400.
1999: Baldwin R L; Tran H; Karlan B Y
Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis.
Gynecologic oncology 1999;74(2):265-71.
1999: Karlan B Y; Baldwin R L; Lopez-Luevanos E; Raffel L J; Barbuto D; Narod S; Platt L D
Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.
American journal of obstetrics and gynecology 1999;180(4):917-28.
1999: Bristow R E; Montz F J; Lagasse L D; Leuchter R S; Karlan B Y
Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Gynecologic oncology 1999;72(3):278-87.
1999: Bristow R E; Baldwin R L; Yamada S D; Korc M; Karlan B Y
Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma.
Cancer 1999;85(3):658-68.
1999: Wilson C A; Ramos L; Villaseñor M R; Anders K H; Press M F; Clarke K; Karlan B; Chen J J; Scully R; Livingston D; Zuch R H; Kanter M H; Cohen S; Calzone F J; Slamon D J
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
Nature genetics 1999;21(2):236-40.
1998: Descamps P; Fondrinier E; Biquard F; Binelli C; Lepinard C; Loisel D; Crvencowitcz G; Platt L D; Karlan B Y
[Is ultrasound screening for ovarian cancer possible in 1998?]
Journal de gynécologie, obstétrique et biologie de la reproduction 1998;27(5):476-81.
1998: Abrahamson J; Moslehi R; Vesprini D; Karlan B; Fishman D; Smotkin D; Ben David Y; Biran H; Fields A; Brunet J S; Narod S A
No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews.
Cancer research 1998;58(14):2919-22.
1998: Chen L M; Karlan B Y
Early detection and risk reduction for familial gynecologic cancers.
Clinical obstetrics and gynecology 1998;41(1):200-14.
1997: Amir M; Shabot M M; Karlan B Y
Surgical intensive care unit care after ovarian cancer surgery: an analysis of indications.
American journal of obstetrics and gynecology 1997;176(6):1389-93.
1997: Grote T H; Pineda L F; Figlin R A; Pendergrass K B; Hesketh P J; Karlan B Y; Reeves J A; Porter L L; Benedict C R; Hahne W F
Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
The cancer journal from Scientific American 1997;3(1):45-51.
1997: Karlan B Y
The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma.
Cancer investigation 1997;15(3):265-9.
1996: Ng W L; Schummer M; Cirisano F D; Baldwin R L; Karlan B Y; Hood L
High-throughput plasmid mini preparations facilitated by micro-mixing.
Nucleic acids research 1996;24(24):5045-7.
1996: Casey G; Lopez M E; Ramos J C; Plummer S J; Arboleda M J; Shaughnessy M; Karlan B; Slamon D J
DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
Oncogene 1996;13(9):1971-81.
1996: Bristow R E; Lagasse L D; Karlan B Y
Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature.
Cancer 1996;78(10):2049-62.
1996: Bristow R E; Karlan B Y
Ovulation induction, infertility, and ovarian cancer risk.
Fertility and sterility 1996;66(4):499-507.
1996: Kim Y B; Barbuto D; Lagasse L D; Karlan B Y
Successful treatment of neuroendocrine small cell carcinoma of the cervix metastatic to regional lymph nodes.
Gynecologic oncology 1996;62(3):411-4.
1996: Cirisano F D; Karlan B Y
The role of the HER-2/neu oncogene in gynecologic cancers.
Journal of the Society for Gynecologic Investigation 1996;3(3):99-105.
1996: Casey A C; Farias-Eisner R; Pisani A L; Cirisano F D; Kim Y B; Muderspach L; Futoran R; Leuchter R S; Lagasse L D; Karlan B Y
What is the role of reassessment laparoscopy in the management of gynecologic cancers in 1995?
Gynecologic oncology 1996;60(3):454-61.
1996: Crvenkovic G; Karlan B Y; Platt L D
Current role of ultrasound in ovarian cancer screening.
Clinical obstetrics and gynecology 1996;39(1):259-67.
1996: Bristow R E; Karlan B Y
The risk of ovarian cancer after treatment for infertility.
Current opinion in obstetrics & gynecology 1996;8(1):32-7.
1995: Karlan B Y
Where are we now and where are we going?
Gynecologic oncology 1995;59(3):315-7.
1995: Karlan B Y; Platt L D
Ovarian cancer screening. The role of ultrasound in early detection.
Cancer 1995;76(10 Suppl):2011-5.
1995: Karlan B Y; Baldwin R L; Cirisano F D; Mamula P W; Jones J; Lagasse L D
Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation.
Gynecologic oncology 1995;59(1):67-74.
1995: Karlan B Y; Jones J; Greenwald M; Lagasse L D
Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro.
American journal of obstetrics and gynecology 1995;173(1):97-104.
1995: Cane P; Azen C; Lopez E; Platt L D; Karlan B Y
Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
Gynecologic oncology 1995;57(2):240-5.
1995: Pisani A L; Barbuto D A; Chen D; Ramos L; Lagasse L D; Karlan B Y
HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma.
Obstetrics and gynecology 1995;85(5 Pt 1):729-34.
1995: Karlan B Y
Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials?
Journal of cellular biochemistry. Supplement 1995;23():227-32.
1994: Karlan B Y; Platt L D
The current status of ultrasound and color Doppler imaging in screening for ovarian cancer.
Gynecologic oncology 1994;55(3 Pt 2):S28-33.
1994: Jones J; Lagasse L D; Karlan B Y
Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines.
Gynecologic oncology 1994;55(3 Pt 1):421-6.
1994: Karlan B Y; Marrs R; Lagasse L D
Advanced-stage ovarian carcinoma presenting during infertility evaluation.
American journal of obstetrics and gynecology 1994;171(5):1377-8.
1994: McGonigle K F; Karlan B Y; Barbuto D A; Leuchter R S; Lagasse L D; Judd H L
Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.
Gynecologic oncology 1994;55(1):126-32.
1994: Farias-Eisner R; Teng F; Oliveira M; Leuchter R; Karlan B; Lagasse L D; Berek J S
The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery.
Gynecologic oncology 1994;55(1):108-10.
1994: Farias-Eisner R; Cirisano F D; Grouse D; Leuchter R S; Karlan B Y; Lagasse L D; Berek J S
Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease.
Gynecologic oncology 1994;53(1):55-8.
1994: Karlan B Y; Jones J; Slamon D J; Lagasse L D
Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.
Gynecologic oncology 1994;53(1):70-7.
1994: Karlan B Y; Krakow D
Genetic aspects of ovarian cancer.
Current opinion in obstetrics & gynecology 1994;6(1):105-10.
1993: Karlan B Y; Hawkins R; Hoh C; Lee M; Tse N; Cane P; Glaspy J
Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma.
Gynecologic oncology 1993;51(2):175-81.
1993: Karlan B Y; Raffel L J; Crvenkovic G; Smrt C; Chen M D; Lopez E; Walla C A; Garber C; Cane P; Sarti D A
A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results.
American journal of obstetrics and gynecology 1993;169(3):494-501.
1993: Cirisano F D; Greenspoon J S; Stenson R; Farias-Eisner R; Karlan B Y; Lagasse L D
The etiology and management of diarrhea in the gynecologic oncology patient.
Gynecologic oncology 1993;50(1):45-8.
1993: Karlan B Y; Hoh C; Tse N; Futoran R; Hawkins R; Glaspy J
Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube.
Gynecologic oncology 1993;49(3):383-8.
1993: Brown J V; Karlan B Y; Greenspoon J S; Rosove M H; Lagasse L D
Perioperative coagulopathy in patients undergoing primary cytoreduction.
Cancer 1993;71(8):2557-61.
1993: McGonigle K F; Lagasse L D; Karlan B Y
Ovarian, uterine, and cervical cancer in the elderly woman.
Clinics in geriatric medicine 1993;9(1):115-30.
1991: Trimble E L; Karlan B Y; Lagasse L D; Hoskins W J
Diagnosing the correct ovarian cancer syndrome.
Obstetrics and gynecology 1991;78(6):1023-6.
1989: Karlan B Y; Rivero J A; Crabtree M E; Littlefield B A
Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells.
Molecular endocrinology (Baltimore, Md.) 1989;3(6):1006-13.
1989: Band V; Karlan B Y; Zurawski V R; Littlefield B A
Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells.
Journal of cellular physiology 1989;138(1):106-14.
1988: Karlan B Y; Amin W; Band V; Zurawski V R; Littlefield B A
Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro.
Gynecologic oncology 1988;31(1):103-12.
1988: Karlan B Y; Amin W; Casper S E; Littlefield B A
Hormonal regulation of CA125 tumor marker expression in human ovarian carcinoma cells: inhibition by glucocorticoids.
Cancer research 1988;48(12):3502-6.
1987: Amin W; Karlan B Y; Littlefield B A
Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations.
Cancer research 1987;47(22):6040-5.
1987: Karlan B Y; Clark A S; Littlefield B A
A highly sensitive chromogenic microtiter plate assay for plasminogen activators which quantitatively discriminates between the urokinase and tissue-type activators.
Biochemical and biophysical research communications 1987;142(1):147-54.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Beth Karlan

Research Profile (preview)

Disorders

Genes & Molecular Sequences

Concepts & Ideas

Physiology

Chemicals & Drugs

Procedures

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Beth Karlan (preview)

All Publications